Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study

NCT06679244 · tracked via the Priya Life Science China tracker

Sponsor

Huashan Hospital

Phase

Not applicable

Started

2024-12-04

Last updated

2025-07-22

Condition(s) studied

Gastric Cancer Patients Undergoing Minimally Invasive Gastrectomy

Investigational drug(s) / intervention(s)

Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure techniqueTotally laparoscopic proximal gastrectomy with double-tract reconstruction

Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique: This is an innovative surgical method applied in proximal gastrectomy. By adding anti reflux structures such as "false gastric fundus" and "false cardia" on the basis of esophageal residual gastric anastomosis, the goal of anti reflux is achieved, while maintaining normal physiological channels and fully utilizing residual gastric function, reducing the difficulty of proximal gastrectomy surgery

Totally laparoscopic proximal gastrectomy with double-tract reconstruction: This is a traditional surgical method that has been widely used in proximal gastrectomy. After disconnecting the proximal stomach, performing Roux-en-Y anastomosis of the esophagus and jejunum firstly, followed by lateral anastomosis of the residual stomach and jejunum. Previous studies have confirmed its safety and effectiveness, but there are also issues of gastric channel disuse and high missed detection rate of residual stomach.

Study summary

This is a prospective study using a multicenter, randomized, controlled, open label, and efficacy validated approach.At present, there is no universally recognized optimal method for gastrointestinal reconstruction after proximal gastrectomy in the surgical treatment of gastric cancer.Author's team has proposed an innovative method named Hao's Esophagogastrostomay by Fisture Technique (HEFT).By adding anti reflux structures such as "false gastric fundus" and "false cardia" to the anastomosis of the residual stomach of the esophagus, not only can the purpose of anti reflux be achieved, but also the normal physiological channel can be maintained, it can fully utilize residual stomach function and reduce the difficulty of surgery.Through retrospective research, our single center has confirmed that HEFT is safe and feasible.On this basis, this study will compare the nutritional status, short- and medium- to long-term safety after laparoscopic HEFT and double-tract reconstruction , in order to evaluate and discover more reasonable digestive tract reconstruction methods after proximal gastrectomy, and to promote the development and popularization of minimally treatment technology for gastric cancer.

This study was jointly conducted by Shanghai-level hospitals (Huashan Hospital ,Shanghai Cancer Center, and Ruijin Hospital), with Huashan Hospital as the leading unit. This study will recruit 52 patients, with 26 patients in the experimental group and 26 patients in the control group. Using a central dynamic randomization method based on minimization, patients are assigned to groups in a 1:1 ratio. Based on the different anastomotic methods used in proximal gastrectomy, patients are divided into a HEFT group (experimental group) and a double-tract reconstruction group (control group).Plan to collect cases for 2 years, and follow up for another year after the last case is enrolled.

The primary endpoint of the study was the body weight loss (BWL) rate at 1 year after surgery. Secondary endpoints: Effect evaluation indicators: hemoglobin level at 1 year after surgery; Serum albumin level at 1 year after surgery; The incidence of anastomotic stenosis 1 year after surgery; Incidence of reflux esophagitis at 1 year after surgery. Evaluation of short-term surgical safety (duration: 7 days): operation time, intraoperative bleeding, anastomotic leakage, pancreatic leakage, and incidence of abdominal infection; Evaluation of medium- and long-term safety after surgery (duration: 36 months): overall survival rate at 3 years after surgery; disease-free survival rate at 3 years after surgery.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. 18 years old ≤ 80 years old; 2. The primary tumor lesion is located in the upper part of the stomach or the esophagogastric junction (Siewert II or III), and it is expected that R0 surgical results can be obtained by performing proximal gastrectomy and D2 dissection； 3. The primary lesion was diagnosed as adenocarcinoma through endoscopic biopsy and histopathological examination; 4. If it is upper gastric adenocarcinoma, the clinical TNM staging based on imaging needs to be cT1N0M0. If it is ductal gastric junction adenocarcinoma, it needs to be cT1-3N0-1M0, and clinical imaging judgment shows no distant gastric lymph node metastasis； 5. Expected survival exceeds 6 months; 6. No history of upper abdominal surgery (excluding laparoscopic cholecystectomy); 7. No chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. were performed before surgery; 8. Preoperative ECOG (Eastern Cooperative Oncology Group) physical status score 0/1; 9. Preoperative ASA (American Society of Anesthesiologists) grading I-III ; 10. Good function of important organs; 11. Sign the patient's informed consent form Exclusion Criteria: 1. Preoperative imaging examination suggests the fusion of enlarged lymph nodes (maximum diameter ≥ 3cm) in the area; 2. Pregnant and lactating women; 3. Suffering from other malignant tumors within 5 years; 4. Preoperative body temperature ≥ 38 ℃ or complicated with infectious diseases requiring systematic treatment; 5. Serious mental illness; 6. Severe respiratory diseases, FEV1\<50% of the expected value; 7. Severe liver and kidney dysfunction; 8. History of unstable angina or heart attack within 6 months; 9. History of cerebral infarction or cerebral hemorrhage within 6 months, excluding old intracavitary infarction; 10. Apply systemic corticosteroid therapy within one month; 11. Patients with complications of gastric cancer (bleeding, perforation, obstruction) requiring emergency surgery; 12. The patient has participated or is currently participating in other clinical studies (within 6 months)

Primary outcome measure(s)

body weight loss（BWL） — From enrollment to 1 year after surgery
Measure the weight before surgery and 1 year after surgery, BWL=(preoperative weight -1 year after surgery weight)/preoperative weight (unit:%)

Trial sites (3)

Facility	City	Region	Status
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine	Shanghai	China	Recruiting
Huashan Hospital, Fudan University	Shanghai	China	Recruiting
Second Department of Gastric Surgery, Fudan University Shanghai Cancer Center,	Shanghai	China	Recruiting

More Huashan Hospital trials in China

Real World Study of End-stage Liver Disease in China Recruiting

Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial Recruiting

Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma Starting soon

Efficacy and Safety of Spinal Cord Stimulation in Patients With Spinal Cord Stimulation Recruiting

RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06679244 on ClinicalTrials.gov ↗ ← All trials in China